Analyzing Female Health Company (The) (VERU) and The Competition

Female Health Company (The) (NASDAQ: VERU) is one of 113 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Female Health Company (The) to similar businesses based on the strength of its dividends, institutional ownership, earnings, risk, analyst recommendations, profitability and valuation.

Institutional and Insider Ownership

5.0% of Female Health Company (The) shares are held by institutional investors. Comparatively, 43.1% of shares of all “Pharmaceuticals” companies are held by institutional investors. 10.9% of Female Health Company (The) shares are held by insiders. Comparatively, 12.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Female Health Company (The) and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Female Health Company (The) N/A N/A -10.47
Female Health Company (The) Competitors $7.79 billion $2.46 billion -0.05

Female Health Company (The)’s competitors have higher revenue and earnings than Female Health Company (The). Female Health Company (The) is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Female Health Company (The) and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Female Health Company (The) 0 0 2 0 3.00
Female Health Company (The) Competitors 793 3421 5868 137 2.52

Female Health Company (The) currently has a consensus price target of $5.00, indicating a potential upside of 151.26%. As a group, “Pharmaceuticals” companies have a potential upside of 22.12%. Given Female Health Company (The)’s stronger consensus rating and higher possible upside, research analysts clearly believe Female Health Company (The) is more favorable than its competitors.

Profitability

This table compares Female Health Company (The) and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Female Health Company (The) -42.02% -16.78% -10.64%
Female Health Company (The) Competitors -3,077.18% -55.53% -9.38%

Risk and Volatility

Female Health Company (The) has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Female Health Company (The)’s competitors have a beta of 0.87, indicating that their average share price is 13% less volatile than the S&P 500.

Summary

Female Health Company (The) beats its competitors on 6 of the 11 factors compared.

Female Health Company (The) Company Profile

Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women’s Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

What are top analysts saying about Female Health Company (The)? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Female Health Company (The) and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit